Lytix Biopharma (OB:LYTIX) Third Quarter 2024 Results
Key Financial Results
- Revenue: kr231.0k (down 94% from 3Q 2023).
- Net loss: kr22.7m (loss widened by 25% from 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Lytix Biopharma Earnings Insights
Looking ahead, revenue is forecast to grow 138% p.a. on average during the next 3 years, compared to a 45% growth forecast for the Biotechs industry in Norway.
Performance of the Norwegian Biotechs industry.
The company's shares are down 13% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Lytix Biopharma has 6 warning signs (and 3 which are concerning) we think you should know about.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OB:LYTIX
Lytix Biopharma
A, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway.
Medium-low with adequate balance sheet.
